Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 6 for:    E3611
Previous Study | Return to List | Next Study

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by National Cancer Institute (NCI)
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01708941
First received: October 15, 2012
Last updated: November 25, 2014
Last verified: November 2014
  Purpose

This randomized phase II trial studies how well ipilimumab with or without high-dose recombinant interferon alpha-2b works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab, may block tumor growth by targeting certain cells. Recombinant interferon alfa-2b may interfere with the growth of tumor cells. It is not yet known whether ipilimumab is more effective with or without high-dose recombinant interferon alfa-2b in treating melanoma.


Condition Intervention Phase
Recurrent Melanoma
Stage IIIA Skin Melanoma
Stage IIIB Skin Melanoma
Stage IIIC Skin Melanoma
Stage IV Skin Melanoma
Biological: Ipilimumab
Biological: Recombinant Interferon Alfa-2b
Other: Laboratory Biomarker Analysis
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-α in Advanced Melanoma

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Progression-free survival [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
    The distribution of PFS will be compared using the log-rank test.


Secondary Outcome Measures:
  • Rate of regimen limiting serious adverse events (AEs), defined as grade 3 or higher immune mediated AE that require steroids or immunosuppressive therapy according to the National Cancer Institute Common Terminology Criteria for Adverse Events v 4.0 [ Time Frame: Up to 6 months ] [ Designated as safety issue: Yes ]
    The regimen limiting serious adverse events rate will be evaluated for each treatment arm.

  • Overall survival [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
    OS data will be described for each treatment arm using the Kaplan-Meier method. OS will also be assessed for ipilimumab 10 mg/kg in comparison to ipilimumab 3 mg/kg.

  • Response rate by RECIST and by immune-related response criteria [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
    Response rate will also be assessed for ipilimumab 10 mg/kg in comparison to ipilimumab 3 mg/kg.

  • PFS [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
    Will be assessed for ipilimumab 10 mg/kg treatment in comparison to ipilimumab 3 mg/kg.


Estimated Enrollment: 88
Study Start Date: January 2013
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A (10 mg/kg ipilimumab, HDI)

INDUCTION PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses and recombinant interferon alfa-2b IV over 20 minutes five days a week for 4 weeks and then SC three times weekly for 8 weeks.

MAINTENANCE PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24 and recombinant interferon alfa-2b SC three times weekly for 48 weeks.

Biological: Ipilimumab
Given IV
Other Names:
  • BMS-734016
  • MDX-010
  • MDX-CTLA4
Biological: Recombinant Interferon Alfa-2b
Given IV or SC
Other Names:
  • Alfatronol
  • Glucoferon
  • Heberon Alfa
  • Sch 30500
  • Urifron
Other: Laboratory Biomarker Analysis
Correlative studies
Experimental: Arm B (10 mg/kg ipilimumab)

INDUCTION PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses.

MAINTENANCE PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24.

Biological: Ipilimumab
Given IV
Other Names:
  • BMS-734016
  • MDX-010
  • MDX-CTLA4
Other: Laboratory Biomarker Analysis
Correlative studies
Experimental: Arm C (3 mg/kg ipilimumab + HDI)

INDUCTION PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses and recombinant interferon alfa-2b IV over 20 minutes five days a week for 4 weeks and then SC three times weekly for 8 weeks.

MAINTENANCE PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24 and recombinant interferon alfa-2b SC three times weekly for 48 weeks.

Biological: Ipilimumab
Given IV
Other Names:
  • BMS-734016
  • MDX-010
  • MDX-CTLA4
Biological: Recombinant Interferon Alfa-2b
Given IV or SC
Other Names:
  • Alfatronol
  • Glucoferon
  • Heberon Alfa
  • Sch 30500
  • Urifron
Other: Laboratory Biomarker Analysis
Correlative studies
Experimental: Arm D (3 mg/kg ipilimumab)

INDUCTION PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses.

MAINTENANCE PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24.

Biological: Ipilimumab
Given IV
Other Names:
  • BMS-734016
  • MDX-010
  • MDX-CTLA4
Other: Laboratory Biomarker Analysis
Correlative studies

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have unresectable stage III or stage IV melanoma, either initial presentation or recurrent, that is of cutaneous origin or unknown primary origin, that is histologically diagnosed
  • No more than one prior systemic therapeutic regimen for unresectable stage III or stage IV melanoma; this includes chemotherapy, biologic therapy, biochemotherapy, or investigational treatment; this does not include any therapies given in the adjuvant setting; however, patients are excluded if they have a history of prior treatment for melanoma (either adjuvant or metastatic disease) with ipilimumab or other cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitor, or prior interferon-alpha treatment for metastatic disease (history of adjuvant interferon-alpha is allowed); there should be a 4-week washout period between last treatment administration and initiation of study therapy
  • Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Patients must not have other significant medical, surgical, or psychiatric conditions or require any medication or treatment that in the opinion of the investigator may interfere with compliance, make the administration of Ipilimumab or HDI hazardous or obscure the interpretation of adverse events (AEs), such as a condition associated with frequent diarrhea; patients must not have an active infection requiring current treatment with parenteral antibiotics
  • Patients must not have a history of inflammatory bowel disease or diverticulitis (history of diverticulosis is allowed)
  • Patients who have other current malignancies are not eligible; patients with other malignancies are eligible if they have been continuously disease free for > 5 years prior to the time of randomization; one exception are patients treated with a curative intent and are continuously disease free for > 3 years; these patients would be considered eligible:

    • Patients with prior history at any time of any in situ cancer, lobular carcinoma of the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia or Clark I melanoma in situ are eligible
    • Patients with prior history of basal or squamous skin cancer are eligible
  • Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (e.g., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed; replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of these classes of medication for at least 2 weeks prior to randomization are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study; exclusion from this study also includes patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjogren's syndrome, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre Syndrome and Myasthenia Gravis); other central nervous system (CNS) autoimmune disease (e.g., poliomyelitis, multiple sclerosis); patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible
  • Due to the possible effect of treatment with ipilimumab on the immunologic response to infectious disease vaccines, patients must not have had any infectious disease vaccination (e.g, standard influenza, H1N1 influenza, pneumococcal, meningococcal, tetanus toxoid) within 4 weeks prior to randomization
  • Women must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study during screening to rule out pregnancy; NOTE: a woman of childbearing potential (WOCBP) is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months); for the purposes of this study, post-menopause is defined as:

    • Amenorrhea >= 24 consecutive months without another cause, or
    • For women with irregular menstrual periods and taking hormone replacement therapy (HRT), a documented serum follicle stimulating hormone (FSH) level >= 35 mIU/mL Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (e.g., vasectomy) should be considered to be of childbearing potential; men of fathering potential and WOCBP must be using an adequate method of contraception or must abstain from sexual intercourse to avoid conception/pregnancy throughout the study and for up to 26 weeks after the last dose of ipilimumab or HDI in such a manner that the risk of pregnancy is minimized; men or WOCBP who are unwilling or unable to strictly follow this requirement are not eligible
  • White blood cells (WBC) >= 3000/uL
  • Absolute neutrophil count (ANC) >= 1500/uL
  • Platelets >= 100 x 10^3/uL
  • Hemoglobin >= 10 g/dL
  • Serum creatinine =< 1.8 mg/dl
  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) for patients with liver metastases and =< 2.0 x ULN for patients without liver metastases
  • Serum bilirubin < 2 x ULN for patients with liver metastases and =< 1.5 x ULN for patients without liver metastases, (except patients with Gilbert's syndrome, who must have a total bilirubin < 3.0 mg/dL)
  • No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
  • Patients must be free of brain metastasis by contrast-enhanced computed tomography (CT)/magnetic resonance imaging (MRI) scans within 4 weeks prior to enrollment; if known to have prior brain metastases, must not have evidence of active brain disease after definitive therapy (surgery, radiation therapy or stereotactic radiosurgery) on two successive MRI evaluations at least 3 months apart (one of which is =< 4 weeks prior to starting the study drugs)
  • All sites of disease must be evaluated within 4 weeks prior to randomization; patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01708941

  Hide Study Locations
Locations
United States, Alabama
University of Alabama at Birmingham Active, not recruiting
Birmingham, Alabama, United States, 35294
United States, Colorado
The Medical Center of Aurora Recruiting
Aurora, Colorado, United States, 80012
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Boulder Community Hospital Recruiting
Boulder, Colorado, United States, 80301
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Boulder Recruiting
Boulder, Colorado, United States, 80304
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Penrose Recruiting
Colorado Springs, Colorado, United States, 80907
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Penrose-Saint Francis Healthcare Recruiting
Colorado Springs, Colorado, United States, 80907
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rose Medical Center Active, not recruiting
Denver, Colorado, United States, 80220
Colorado Cancer Research Program CCOP Active, not recruiting
Denver, Colorado, United States, 80224-2522
Porter Adventist Hospital Recruiting
Denver, Colorado, United States, 80210
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Presbyterian - Saint Lukes Medical Center - Health One Recruiting
Denver, Colorado, United States, 80218
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Exempla Saint Joseph Hospital Recruiting
Denver, Colorado, United States, 80218
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Comprehensive Cancer Care and Research Institute of Colorado LLC Recruiting
Englewood, Colorado, United States, 80113
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Swedish Medical Center Recruiting
Englewood, Colorado, United States, 80113
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
North Colorado Medical Center Recruiting
Greeley, Colorado, United States, 80631
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Saint Anthony Hospital Recruiting
Lakewood, Colorado, United States, 80228
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Littleton Adventist Hospital Recruiting
Littleton, Colorado, United States, 80122
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Sky Ridge Medical Center Recruiting
Lone Tree, Colorado, United States, 80124
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Longmont United Hospital Active, not recruiting
Longmont, Colorado, United States, 80501
McKee Medical Center Recruiting
Loveland, Colorado, United States, 80539
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Parker Adventist Hospital Recruiting
Parker, Colorado, United States, 80138
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Parker Recruiting
Parker, Colorado, United States, 80138
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Saint Mary Corwin Medical Center Active, not recruiting
Pueblo, Colorado, United States, 81004
Exempla Lutheran Medical Center Recruiting
Wheat Ridge, Colorado, United States, 80033
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
United States, Connecticut
Saint Francis Hospital and Medical Center Recruiting
Hartford, Connecticut, United States, 06105
Contact: Philip J. Stella    734-712-4673      
Principal Investigator: Philip J. Stella         
United States, Delaware
Beebe Medical Center Active, not recruiting
Lewes, Delaware, United States, 19958
Delaware Clinical and Laboratory Physicians PA Active, not recruiting
Newark, Delaware, United States, 19713
Christiana Gynecologic Oncology LLC Active, not recruiting
Newark, Delaware, United States, 19713
Christiana Care Health System-Christiana Hospital Active, not recruiting
Newark, Delaware, United States, 19718
Helen F Graham Cancer Center Active, not recruiting
Newark, Delaware, United States, 19713
Medical Oncology Hematology Consultants PA Active, not recruiting
Newark, Delaware, United States, 19713
Regional Hematology and Oncology PA Active, not recruiting
Newark, Delaware, United States, 19713
Beebe Health Campus Active, not recruiting
Rehoboth Beach, Delaware, United States, 19971
Nanticoke Memorial Hospital Active, not recruiting
Seaford, Delaware, United States, 19973
Christiana Care Health System-Wilmington Hospital Active, not recruiting
Wilmington, Delaware, United States, 19801
United States, Georgia
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler Active, not recruiting
Savannah, Georgia, United States, 31405
United States, Idaho
Saint Alphonsus Cancer Care Center-Boise Recruiting
Boise, Idaho, United States, 83706
Contact: Philip J. Stella    734-712-4673      
Principal Investigator: Philip J. Stella         
United States, Illinois
Rush - Copley Medical Center Active, not recruiting
Aurora, Illinois, United States, 60504
Illinois CancerCare-Bloomington Active, not recruiting
Bloomington, Illinois, United States, 61701
Saint Joseph Medical Center Active, not recruiting
Bloomington, Illinois, United States, 61701
Illinois CancerCare-Canton Active, not recruiting
Canton, Illinois, United States, 61520
Illinois CancerCare-Carthage Active, not recruiting
Carthage, Illinois, United States, 62321
Centralia Oncology Clinic Active, not recruiting
Centralia, Illinois, United States, 62801
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Timothy M. Kuzel    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Timothy M. Kuzel         
Carle on Vermilion Active, not recruiting
Danville, Illinois, United States, 61832
Cancer Care Center of Decatur Active, not recruiting
Decatur, Illinois, United States, 62526
Decatur Memorial Hospital Active, not recruiting
Decatur, Illinois, United States, 62526
Carle Physician Group-Effingham Active, not recruiting
Effingham, Illinois, United States, 62401
Crossroads Cancer Center Active, not recruiting
Effingham, Illinois, United States, 62401
Illinois CancerCare-Eureka Active, not recruiting
Eureka, Illinois, United States, 61530
Illinois CancerCare Galesburg Active, not recruiting
Galesburg, Illinois, United States, 61401
Illinois CancerCare-Galesburg Cottage Plaza Office Recruiting
Galesburg, Illinois, United States, 61401
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Ingalls Memorial Hospital Active, not recruiting
Harvey, Illinois, United States, 60426
Hematology Oncology Associates of Illinois-Highland Park Recruiting
Highland Park, Illinois, United States, 60035
Contact: Timothy M. Kuzel    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Timothy M. Kuzel         
North Shore Hematology Oncology Recruiting
Libertyville, Illinois, United States, 60048
Contact: Timothy M. Kuzel    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Timothy M. Kuzel         
Illinois CancerCare-Macomb Active, not recruiting
Macomb, Illinois, United States, 61455
Carle Physician Group-Mattoon/Charleston Active, not recruiting
Mattoon, Illinois, United States, 61938
Spector, David MD (UIA Investigator) Active, not recruiting
Moline, Illinois, United States, 61265
Porubcin, Michael MD (UIA Investigator) Terminated
Moline, Illinois, United States, 61265
Garneau, Stewart C MD (UIA Investigator) Active, not recruiting
Moline, Illinois, United States, 61265
Trinity Medical Center Active, not recruiting
Moline, Illinois, United States, 61265
Illinois CancerCare-Monmouth Terminated
Monmouth, Illinois, United States, 61462
Illinois Cancer Specialists-Niles Recruiting
Niles, Illinois, United States, 60714
Contact: Timothy M. Kuzel    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Timothy M. Kuzel         
Community Cancer Center Foundation Terminated
Normal, Illinois, United States, 61761
Illinois CancerCare-Ottawa Clinic Active, not recruiting
Ottawa, Illinois, United States, 61350
Ottawa Regional Hospital and Healthcare Center Active, not recruiting
Ottawa, Illinois, United States, 61350
Illinois CancerCare-Pekin Active, not recruiting
Pekin, Illinois, United States, 61554
Pekin Cancer Treatment Center Active, not recruiting
Pekin, Illinois, United States, 61554
Illinois CancerCare-Peoria Active, not recruiting
Peoria, Illinois, United States, 61615
Proctor Hospital Terminated
Peoria, Illinois, United States, 61614
Methodist Medical Center of Illinois Active, not recruiting
Peoria, Illinois, United States, 61603
OSF Saint Francis Medical Center Active, not recruiting
Peoria, Illinois, United States, 61637
Illinois Oncology Research Association CCOP Terminated
Peoria, Illinois, United States, 61615
Illinois CancerCare-Peru Active, not recruiting
Peru, Illinois, United States, 61354
Swedish American Hospital Withdrawn
Rockford, Illinois, United States, 61104
SwedishAmerican Regional Cancer Center/ACT Active, not recruiting
Rockford, Illinois, United States, 61107
Hematology Oncology Associates of Illinois - Skokie Recruiting
Skokie, Illinois, United States, 60076
Contact: Timothy M. Kuzel    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Timothy M. Kuzel         
Memorial Medical Center Active, not recruiting
Springfield, Illinois, United States, 62781-0001
Carle Cancer Center Active, not recruiting
Urbana, Illinois, United States, 61801
The Carle Foundation Hospital Active, not recruiting
Urbana, Illinois, United States, 61801
Rush-Copley Healthcare Center Active, not recruiting
Yorkville, Illinois, United States, 60560
United States, Indiana
IU Health Central Indiana Cancer Centers-East Active, not recruiting
Indianapolis, Indiana, United States, 46219
Franciscan Saint Anthony Health-Michigan City Active, not recruiting
Michigan City, Indiana, United States, 46360
Woodland Cancer Care Center Active, not recruiting
Michigan City, Indiana, United States, 46360
United States, Iowa
Mary Greeley Medical Center Recruiting
Ames, Iowa, United States, 50010
Contact: Joseph J. Merchant    515-239-2621      
Principal Investigator: Joseph J. Merchant         
McFarland Clinic PC-William R Bliss Cancer Center Recruiting
Ames, Iowa, United States, 50010
Contact: Joseph J. Merchant    515-239-2621      
Principal Investigator: Joseph J. Merchant         
Constantinou, Costas L MD (UIA Investigator) Active, not recruiting
Bettendorf, Iowa, United States, 52722
McFarland Clinic PC-Boone Recruiting
Boone, Iowa, United States, 50036
Contact: Joseph J. Merchant    515-239-2621      
Principal Investigator: Joseph J. Merchant         
Medical Oncology and Hematology Associates-West Des Moines Active, not recruiting
Clive, Iowa, United States, 50325
Medical Oncology and Hematology Associates-Des Moines Active, not recruiting
Des Moines, Iowa, United States, 50309
Iowa Methodist Medical Center Active, not recruiting
Des Moines, Iowa, United States, 50309
Iowa Oncology Research Association CCOP Active, not recruiting
Des Moines, Iowa, United States, 50309
Iowa Lutheran Hospital Active, not recruiting
Des Moines, Iowa, United States, 50316
Medical Oncology and Hematology Associates-Laurel Active, not recruiting
Des Moines, Iowa, United States, 50314
McFarland Clinic PC-Trinity Cancer Center Recruiting
Fort Dodge, Iowa, United States, 50501
Contact: Joseph J. Merchant    515-239-2621      
Principal Investigator: Joseph J. Merchant         
McFarland Clinic PC-Jefferson Recruiting
Jefferson, Iowa, United States, 50129
Contact: Joseph J. Merchant    515-239-2621      
Principal Investigator: Joseph J. Merchant         
McFarland Clinic PC-Marshalltown Recruiting
Marshalltown, Iowa, United States, 50158
Contact: Joseph J. Merchant    515-239-2621      
Principal Investigator: Joseph J. Merchant         
Mercy Medical Center-Sioux City Terminated
Sioux City, Iowa, United States, 51104
Saint Luke's Regional Medical Center Terminated
Sioux City, Iowa, United States, 51104
Siouxland Hematology Oncology Associates Recruiting
Sioux City, Iowa, United States, 51101
Contact: Donald B. Wender    712-252-0088      
Principal Investigator: Donald B. Wender         
Methodist West Hospital Active, not recruiting
West Des Moines, Iowa, United States, 50266-7700
United States, Kansas
Cancer Center of Kansas - Chanute Recruiting
Chanute, Kansas, United States, 66720
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Dodge City Recruiting
Dodge City, Kansas, United States, 67801
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - El Dorado Recruiting
El Dorado, Kansas, United States, 67042
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Fort Scott Recruiting
Fort Scott, Kansas, United States, 66701
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas-Independence Recruiting
Independence, Kansas, United States, 67301
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas-Kingman Recruiting
Kingman, Kansas, United States, 67068
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Lawrence Memorial Hospital Recruiting
Lawrence, Kansas, United States, 66044
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas-Liberal Recruiting
Liberal, Kansas, United States, 67901
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas-Manhattan Terminated
Manhattan, Kansas, United States, 66502
Cancer Center of Kansas - McPherson Terminated
McPherson, Kansas, United States, 67460
Cancer Center of Kansas - Newton Recruiting
Newton, Kansas, United States, 67114
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Parsons Recruiting
Parsons, Kansas, United States, 67357
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Pratt Recruiting
Pratt, Kansas, United States, 67124
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Salina Recruiting
Salina, Kansas, United States, 67401
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Wellington Recruiting
Wellington, Kansas, United States, 67152
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas-Wichita Medical Arts Tower Recruiting
Wichita, Kansas, United States, 67208
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Main Office Recruiting
Wichita, Kansas, United States, 67214
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Associates In Womens Health Recruiting
Wichita, Kansas, United States, 67208
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Via Christi Regional Medical Center Recruiting
Wichita, Kansas, United States, 67214
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Wichita CCOP Terminated
Wichita, Kansas, United States, 67214
Cancer Center of Kansas - Winfield Recruiting
Winfield, Kansas, United States, 67156
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
United States, Louisiana
Ochsner Health Center-Summa Recruiting
Baton Rouge, Louisiana, United States, 70809
Contact: Jyotsna Fuloria    888-562-4763      
Principal Investigator: Jyotsna Fuloria         
Ochsner Baptist Medical Center Recruiting
New Orleans, Louisiana, United States, 70115
Contact: Jyotsna Fuloria    888-562-4763      
Principal Investigator: Jyotsna Fuloria         
Ochsner Medical Center Jefferson Recruiting
New Orleans, Louisiana, United States, 70121
Contact: Jyotsna Fuloria    888-562-4763      
Principal Investigator: Jyotsna Fuloria         
United States, Maryland
Greater Baltimore Medical Center Active, not recruiting
Baltimore, Maryland, United States, 21204
Union Hospital of Cecil County Terminated
Elkton MD, Maryland, United States, 21921
United States, Michigan
Bixby Medical Center Active, not recruiting
Adrian, Michigan, United States, 49221
Hickman Cancer Center Active, not recruiting
Adrian, Michigan, United States, 49221
Michigan Cancer Research Consortium Community Clinical Oncology Program Terminated
Ann Arbor, Michigan, United States, 48106
Saint Joseph Mercy Hospital Recruiting
Ann Arbor, Michigan, United States, 48106-0995
Contact: Philip J. Stella    734-712-4673      
Principal Investigator: Philip J. Stella         
Oakwood Hospital and Medical Center Recruiting
Dearborn, Michigan, United States, 48124
Contact: Philip J. Stella    734-712-4673      
Principal Investigator: Philip J. Stella         
Saint John Hospital and Medical Center Recruiting
Detroit, Michigan, United States, 48236
Contact: Philip J. Stella    734-712-4673      
Principal Investigator: Philip J. Stella         
Green Bay Oncology - Escanaba Active, not recruiting
Escanaba, Michigan, United States, 49431
Genesys Hurley Cancer Institute Recruiting
Flint, Michigan, United States, 48503
Contact: Philip J. Stella    734-712-4673      
Principal Investigator: Philip J. Stella         
Hurley Medical Center Recruiting
Flint, Michigan, United States, 48502
Contact: Philip J. Stella    734-712-4673      
Principal Investigator: Philip J. Stella         
Green Bay Oncology - Iron Mountain Active, not recruiting
Iron Mountain, Michigan, United States, 49801
Allegiance Health Recruiting
Jackson, Michigan, United States, 49201
Contact: Philip J. Stella    734-712-4673      
Principal Investigator: Philip J. Stella         
Sparrow Hospital Recruiting
Lansing, Michigan, United States, 48912
Contact: Philip J. Stella    734-712-4673      
Principal Investigator: Philip J. Stella         
Saint Mary Mercy Hospital Recruiting
Livonia, Michigan, United States, 48154
Contact: Philip J. Stella    734-712-4673      
Principal Investigator: Philip J. Stella         
Community Cancer Center of Monroe Terminated
Monroe, Michigan, United States, 48162
Mercy Memorial Hospital Terminated
Monroe, Michigan, United States, 48162
Saint Joseph Mercy Port Huron Recruiting
Port Huron, Michigan, United States, 48060
Contact: Philip J. Stella    734-712-4673      
Principal Investigator: Philip J. Stella         
Saint Mary's of Michigan Recruiting
Saginaw, Michigan, United States, 48601
Contact: Philip J. Stella    734-712-4673      
Principal Investigator: Philip J. Stella         
United States, Minnesota
Fairview Ridges Hospital Active, not recruiting
Burnsville, Minnesota, United States, 55337
Mercy Hospital Active, not recruiting
Coon Rapids, Minnesota, United States, 55433
Fairview-Southdale Hospital Active, not recruiting
Edina, Minnesota, United States, 55435
Unity Hospital Active, not recruiting
Fridley, Minnesota, United States, 55432
Hutchinson Area Health Care Active, not recruiting
Hutchinson, Minnesota, United States, 55350
Saint John's Hospital - Healtheast Active, not recruiting
Maplewood, Minnesota, United States, 55109
Minnesota Oncology Hematology PA-Maplewood Active, not recruiting
Maplewood, Minnesota, United States, 55109
Abbott-Northwestern Hospital Active, not recruiting
Minneapolis, Minnesota, United States, 55407
Health Partners Inc Active, not recruiting
Minneapolis, Minnesota, United States, 55454
Hennepin County Medical Center Active, not recruiting
Minneapolis, Minnesota, United States, 55415
New Ulm Medical Center Active, not recruiting
New Ulm, Minnesota, United States, 56073
North Memorial Medical Health Center Active, not recruiting
Robbinsdale, Minnesota, United States, 55422
Metro-Minnesota CCOP Terminated
Saint Louis Park, Minnesota, United States, 55416
Park Nicollet Clinic - Saint Louis Park Active, not recruiting
Saint Louis Park, Minnesota, United States, 55416
Regions Hospital Active, not recruiting
Saint Paul, Minnesota, United States, 55101
United Hospital Active, not recruiting
Saint Paul, Minnesota, United States, 55102
Saint Francis Regional Medical Center Active, not recruiting
Shakopee, Minnesota, United States, 55379
Lakeview Hospital Active, not recruiting
Stillwater, Minnesota, United States, 55082
Ridgeview Medical Center Active, not recruiting
Waconia, Minnesota, United States, 55387
Rice Memorial Hospital Active, not recruiting
Willmar, Minnesota, United States, 56201
Minnesota Oncology and Hematology PA-Woodbury Active, not recruiting
Woodbury, Minnesota, United States, 55125
United States, Missouri
Saint Francis Medical Center Active, not recruiting
Cape Girardeau, Missouri, United States, 63703
United States, Nebraska
Nebraska Cancer Research Center Terminated
Lincoln, Nebraska, United States, 68510
Nebraska Hematology and Oncology Recruiting
Lincoln, Nebraska, United States, 68506
Contact: Gamini S. Soori    402-991-8070ext202    mwilwerding@mvcc.cc   
Principal Investigator: Gamini S. Soori         
Alegent Health Bergan Mercy Medical Center Active, not recruiting
Omaha, Nebraska, United States, 68124
Oncology Hematology West PC Recruiting
Omaha, Nebraska, United States, 68130
Contact: Gamini S. Soori    402-991-8070ext202    mwilwerding@mvcc.cc   
Principal Investigator: Gamini S. Soori         
Alegent Health Lakeside Hospital Active, not recruiting
Omaha, Nebraska, United States, 68130
Creighton University Medical Center Active, not recruiting
Omaha, Nebraska, United States, 68131
Missouri Valley Cancer Consortium Terminated
Omaha, Nebraska, United States, 68106
Oncology Hematology West Recruiting
Omaha, Nebraska, United States, 68124
Contact: Gamini S. Soori    402-991-8070ext202    mwilwerding@mvcc.cc   
Principal Investigator: Gamini S. Soori         
Alegent Health Immanuel Medical Center Active, not recruiting
Omaha, Nebraska, United States, 68122
Regional West Medical Center Recruiting
Scottsbluff, Nebraska, United States, 69361
Contact: Gamini S. Soori    402-991-8070ext202    mwilwerding@mvcc.cc   
Principal Investigator: Gamini S. Soori         
United States, New Jersey
Cooper Hospital University Medical Center Active, not recruiting
Camden, New Jersey, United States, 08103
Veterans Adminstration New Jersey Health Care System Active, not recruiting
East Orange, New Jersey, United States, 07018-1095
Hunterdon Medical Center Terminated
Flemington, New Jersey, United States, 08822
Rutgers Cancer Institute of New Jersey Active, not recruiting
New Brunswick, New Jersey, United States, 08903
United States, New York
New York Oncology Hematology PC -Albany Medical Center Active, not recruiting
Albany, New York, United States, 12208
Stony Brook University Medical Center Active, not recruiting
Stony Brook, New York, United States, 11794
United States, Ohio
Summa Akron City Hospital/Cooper Cancer Center Active, not recruiting
Akron, Ohio, United States, 44304
Strecker Cancer Center-Belpre Active, not recruiting
Belpre, Ohio, United States, 45714
Toledo Clinic Cancer Centers-Bowling Green Terminated
Bowling Green, Ohio, United States, 43402
Adena Regional Medical Center Active, not recruiting
Chillicothe, Ohio, United States, 45601
MetroHealth Medical Center Active, not recruiting
Cleveland, Ohio, United States, 44109
Columbus Oncology and Hematology Associates Inc Active, not recruiting
Columbus, Ohio, United States, 43214
Doctors Hospital Active, not recruiting
Columbus, Ohio, United States, 43228
Grant Medical Center Active, not recruiting
Columbus, Ohio, United States, 43215
Mount Carmel Health Center West Active, not recruiting
Columbus, Ohio, United States, 43222
Riverside Methodist Hospital Active, not recruiting
Columbus, Ohio, United States, 43214
The Mark H Zangmeister Center Active, not recruiting
Columbus, Ohio, United States, 43219
Columbus CCOP Terminated
Columbus, Ohio, United States, 43215
Grady Memorial Hospital Active, not recruiting
Delaware, Ohio, United States, 43015
Delaware Health Center-Grady Cancer Center Active, not recruiting
Delaware, Ohio, United States, 43015
Delaware Radiation Oncology Active, not recruiting
Delaware, Ohio, United States, 43015
Fairfield Medical Center Active, not recruiting
Lancaster, Ohio, United States, 43130
Lancaster Radiation Oncology Terminated
Lancaster, Ohio, United States, 43130
Lima Memorial Hospital Terminated
Lima, Ohio, United States, 45804
Marietta Memorial Hospital Active, not recruiting
Marietta, Ohio, United States, 45750
Toledo Clinic Cancer Centers-Maumee Active, not recruiting
Maumee, Ohio, United States, 43537
Knox Community Hospital Active, not recruiting
Mount Vernon, Ohio, United States, 43050
Licking Memorial Hospital Active, not recruiting
Newark, Ohio, United States, 43055
Newark Radiation Oncology Active, not recruiting
Newark, Ohio, United States, 43055
Saint Charles Hospital Active, not recruiting
Oregon, Ohio, United States, 43616
Toledo Clinic Cancer Centers-Oregon Terminated
Oregon, Ohio, United States, 43616
Southern Ohio Medical Center Active, not recruiting
Portsmouth, Ohio, United States, 45662
Springfield Regional Medical Center Active, not recruiting
Springfield, Ohio, United States, 45505
Flower Hospital Active, not recruiting
Sylvania, Ohio, United States, 43560
Mercy Hospital of Tiffin Terminated
Tiffin, Ohio, United States, 44883
Mercy Saint Anne Hospital Active, not recruiting
Toledo, Ohio, United States, 43623
University of Toledo Active, not recruiting
Toledo, Ohio, United States, 43614
The Toledo Hospital/Toledo Children's Hospital Terminated
Toledo, Ohio, United States, 43606
Toledo Clinic Cancer Centers-Toledo Active, not recruiting
Toledo, Ohio, United States, 43623
Toledo Community Hospital Oncology Program CCOP Terminated
Toledo, Ohio, United States, 43617
Saint Vincent Mercy Medical Center Terminated
Toledo, Ohio, United States, 43608
Fulton County Health Center Terminated
Wauseon, Ohio, United States, 43567
Saint Ann's Hospital Active, not recruiting
Westerville, Ohio, United States, 43081
Genesis HealthCare System Active, not recruiting
Zanesville, Ohio, United States, 43701
United States, Oklahoma
Natalie Warren Bryant Cancer Center at Saint Francis Withdrawn
Tulsa, Oklahoma, United States, 74136
United States, Pennsylvania
Geisinger Medical Center Recruiting
Danville, Pennsylvania, United States, 17822
Contact: Christian S. Adonizio    570-271-5251      
Principal Investigator: Christian S. Adonizio         
Geisinger Medical Center-Cancer Center Hazleton Recruiting
Hazleton, Pennsylvania, United States, 18201
Contact: Christian S. Adonizio    570-271-5251      
Principal Investigator: Christian S. Adonizio         
Geisinger Medical Oncology at Evangelical Community Hospital Recruiting
Lewisburg, Pennsylvania, United States, 17837
Contact: Christian S. Adonizio    570-271-5251      
Principal Investigator: Christian S. Adonizio         
Lewistown Hospital Recruiting
Lewistown, Pennsylvania, United States, 17044
Contact: Christian S. Adonizio    570-271-5251      
Principal Investigator: Christian S. Adonizio         
Fox Chase Cancer Center Active, not recruiting
Philadelphia, Pennsylvania, United States, 19111
University of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Contact: Ahmad A. Tarhini    412-647-8073      
Principal Investigator: Ahmad A. Tarhini         
Geisinger Medical Oncology-Pottsville Active, not recruiting
Pottsville, Pennsylvania, United States, 17901
Geisinger Medical Group Recruiting
State College, Pennsylvania, United States, 16801
Contact: Christian S. Adonizio    570-271-5251      
Principal Investigator: Christian S. Adonizio         
Geisinger Wyoming Valley Recruiting
Wilkes-Barre, Pennsylvania, United States, 18711
Contact: Christian S. Adonizio    570-271-5251      
Principal Investigator: Christian S. Adonizio         
United States, Tennessee
Erlanger Medical Center Active, not recruiting
Chattanooga, Tennessee, United States, 37403
United States, Virginia
Fredericksburg Oncology Inc Terminated
Fredericksburg, Virginia, United States, 22401
United States, West Virginia
West Virginia University Charleston Active, not recruiting
Charleston, West Virginia, United States, 25304
United States, Wisconsin
Aurora Cancer Care-Burlington Recruiting
Burlington, Wisconsin, United States, 53105
Contact: Rubina Qamar    888-709-2080      
Principal Investigator: Rubina Qamar         
Aurora Cancer Care-Southern Lakes Recruiting
Elkhorn, Wisconsin, United States, 53121
Contact: Rubina Qamar    888-709-2080      
Principal Investigator: Rubina Qamar         
Aurora Cancer Care-Grafton Recruiting
Grafton, Wisconsin, United States, 53024
Contact: Rubina Qamar    888-709-2080      
Principal Investigator: Rubina Qamar         
Aurora BayCare Medical Center Recruiting
Green Bay, Wisconsin, United States, 54311-6519
Contact: Dhimant R. Patel    800-252-2990      
Principal Investigator: Dhimant R. Patel         
Green Bay Oncology at Saint Vincent Hospital Active, not recruiting
Green Bay, Wisconsin, United States, 54301-3526
Saint Vincent Hospital Active, not recruiting
Green Bay, Wisconsin, United States, 54301
Saint Mary's Hospital Active, not recruiting
Green Bay, Wisconsin, United States, 54303
Green Bay Oncology Limited at Saint Mary's Hospital Active, not recruiting
Green Bay, Wisconsin, United States, 54303
UW Cancer Center Johnson Creek Active, not recruiting
Johnson Creek, Wisconsin, United States, 53038
Aurora Cancer Care-Kenosha South Recruiting
Kenosha, Wisconsin, United States, 53142
Contact: Rubina Qamar    888-709-2080      
Principal Investigator: Rubina Qamar         
Gundersen Lutheran Medical Center Active, not recruiting
La Crosse, Wisconsin, United States, 54601
University of Wisconsin Hospital and Clinics Active, not recruiting
Madison, Wisconsin, United States, 53792
Holy Family Memorial Hospital Active, not recruiting
Manitowoc, Wisconsin, United States, 54221
Bay Area Medical Center Active, not recruiting
Marinette, Wisconsin, United States, 54143
Vince Lombardi Cancer Clinic-Marinette Recruiting
Marinette, Wisconsin, United States, 54143
Contact: Dhimant R. Patel    800-252-2990      
Principal Investigator: Dhimant R. Patel         
Aurora Advanced Healthcare Inc-Menomonee Falls Recruiting
Menomonee Falls, Wisconsin, United States, 53051
Contact: Rubina Qamar    888-709-2080      
Principal Investigator: Rubina Qamar         
Aurora Sinai Medical Center Recruiting
Milwaukee, Wisconsin, United States, 53233
Contact: Rubina Qamar    888-709-2080      
Principal Investigator: Rubina Qamar         
Aurora Saint Luke's Medical Center Recruiting
Milwaukee, Wisconsin, United States, 53215
Contact: Rubina Qamar    888-709-2080      
Principal Investigator: Rubina Qamar         
Aurora Cancer Care-Milwaukee Recruiting
Milwaukee, Wisconsin, United States, 53209
Contact: Rubina Qamar    888-709-2080      
Principal Investigator: Rubina Qamar         
Froedtert and the Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Stuart J. Wong    414-805-4380      
Principal Investigator: Stuart J. Wong         
Wheaton Franciscan Healthcare - Saint Joseph Active, not recruiting
Milwaukee, Wisconsin, United States, 53210
Cancer Center of Western Wisconsin Active, not recruiting
New Richmond, Wisconsin, United States, 54017
Green Bay Oncology - Oconto Falls Active, not recruiting
Oconto Falls, Wisconsin, United States, 54154
Vince Lombardi Cancer Clinic - Oshkosh Recruiting
Oshkosh, Wisconsin, United States, 54904
Contact: Dhimant R. Patel    800-252-2990      
Principal Investigator: Dhimant R. Patel         
Aurora Cancer Care-Racine Recruiting
Racine, Wisconsin, United States, 53406-5661
Contact: Rubina Qamar    888-709-2080      
Principal Investigator: Rubina Qamar         
Saint Nicholas Hospital Active, not recruiting
Sheboygan, Wisconsin, United States, 53081
Vince Lombardi Cancer Clinic-Sheboygan Recruiting
Sheboygan, Wisconsin, United States, 53081
Contact: Dhimant R. Patel    800-252-2990      
Principal Investigator: Dhimant R. Patel         
Green Bay Oncology - Sturgeon Bay Active, not recruiting
Sturgeon Bay, Wisconsin, United States, 54235
Aurora Medical Center in Summit Recruiting
Summit, Wisconsin, United States, 53066
Contact: Dhimant R. Patel    800-252-2990      
Principal Investigator: Dhimant R. Patel         
Vince Lombardi Cancer Clinic Recruiting
Two Rivers, Wisconsin, United States, 54241
Contact: Dhimant R. Patel    800-252-2990      
Principal Investigator: Dhimant R. Patel         
Aurora Cancer Care-Waukesha Recruiting
Waukesha, Wisconsin, United States, 53188
Contact: Rubina Qamar    888-709-2080      
Principal Investigator: Rubina Qamar         
Aurora Cancer Care-Milwaukee West Recruiting
Wauwatosa, Wisconsin, United States, 53226
Contact: Rubina Qamar    888-709-2080      
Principal Investigator: Rubina Qamar         
Aurora West Allis Medical Center Recruiting
West Allis, Wisconsin, United States, 53227
Contact: Rubina Qamar    888-709-2080      
Principal Investigator: Rubina Qamar         
Sponsors and Collaborators
Investigators
Principal Investigator: Ahmad Tarhini ECOG-ACRIN Cancer Research Group
  More Information

No publications provided

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT01708941     History of Changes
Other Study ID Numbers: NCI-2012-01932, NCI-2012-01932, CDR0000741878, ECOG-E3611, E3611, E3611, U10CA021115, U10CA180820
Study First Received: October 15, 2012
Last Updated: November 25, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Melanoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Interferon-alpha
Interferons
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014